Ventricular Tachycardia Management

Introduction to VT Management

Ventricular tachycardia (VT) management involves various pharmacological and device-based therapies, with the goal of preventing sudden cardiac death and improving quality of life, as recommended by the American College of Cardiology and the European Heart Journal 1, 2

Beta-blockers, such as metoprolol and propranolol, are recommended as first-line therapy for long-term management of VT, particularly during pregnancy 2
Amiodarone is the most effective antiarrhythmic for VT suppression, particularly useful as adjunct to ICD therapy to suppress symptomatic ventricular tachyarrhythmias, and can be used in patients with structural heart disease 3
Amiodarone, sotalol, and/or beta-blockers are recommended pharmacological adjuncts to ICD therapy for secondary prevention in survivors of VT/VF and for primary prevention in high-risk patients 3
Sotalol or procainamide IV can be considered for acute conversion of hemodynamically stable VT 2
Amiodarone IV should be considered for acute conversion of sustained VT when other options fail 2
A cardioselective beta-blocker, such as metoprolol or bisoprolol, should be chosen for patients with pulmonary disease concerns, and nadolol should be considered for patients with catecholaminergic polymorphic VT, as recommended by the American College of Cardiology 1
A beta-blocker + flecainide combination may be effective for catecholaminergic polymorphic VT, as suggested by the American College of Cardiology 1
Verapamil or diltiazem should not be used in patients with VT and pre-excitation syndromes, and digoxin should be avoided in patients with pre-excitation, as advised by the American Heart Association 4

Implantable Cardioverter Defibrillator (ICD) is recommended for secondary prevention in survivors of VT/VF and for primary prevention in high-risk patients, with medications typically used as adjuncts to ICD therapy 3
ICD may be considered in specific muscular dystrophies when there's evidence of ventricular arrhythmias 2
ICD programming should be reassessed to minimize inappropriate shocks and optimize therapy for VF if beta-blocker uptitration fails despite reaching maximum tolerated doses, as recommended by the American College of Cardiology 1

Patients with neuromuscular disorders who have ventricular arrhythmias should be treated the same as patients without neuromuscular disorders 2
Heart failure patients should start with lower doses and slower uptitration, and be monitored closely for worsening heart failure symptoms, as recommended by the American College of Cardiology 1
Elderly patients should start with approximately half the usual adult dose, and have more gradual uptitration, with a greater risk of bradycardia and hypotension, as suggested by the American College of Cardiology 1
Patients with refractory ventricular tachycardia (VT) should have an implantable cardioverter-defibrillator (ICD) if indicated, and acute management of sustained VT episodes should be addressed, such as cardioversion for hemodynamically unstable patients, as recommended by the American College of Cardiology and the European Heart Journal 1, 2

Beta-blocker withdrawal can lead to upregulation of beta-receptors, sympathetic rebound, and loss of rate control, increasing SVT risk, and should be done gradually, reducing the dose by 25-50% every 1-2 weeks, with extended tapering for long-term users and close monitoring, as recommended by the American College of Cardiology 4, 5
Vagal maneuvers, adenosine, and intravenous calcium channel blockers or reintroduction of beta-blockade should be used to manage SVT during metoprolol withdrawal, and synchronized cardioversion should be used for hemodynamic instability, as recommended by the American College of Cardiology 4